Hou Zhen, Zhou Jing, Ma Xiang, Fan Lu, Liao Lianming, Liu Jiayin
Center of Clinical Reproductive Medicine, Department of Obstetrics and Gynecology, First Affiliated Hospital of Nanjing Medical University, Nanjing, People's Republic of China.
Fertil Steril. 2008 Jan;89(1):42-51. doi: 10.1016/j.fertnstert.2007.01.044. Epub 2007 May 4.
To determine the role of interleukin-1 receptor type II (IL-1RII) in the pathogenesis of endometriosis.
Cultures of endometrial cells exposed to soluble IL-1RII or the recombinant adenovirus of IL-1RII (rAd-RII).
Gynecology clinic and human reproduction research laboratory.
PATIENT(S): Women with endometriosis undergoing hysterectomy.
INTERVENTION(S): Cell culture media were collected 12 hours after addition of soluble IL-1RII or infection of rAd-RII.
MAIN OUTCOME MEASURE(S): The levels of IL-6 and IL-8 in the culture media were measured via enzyme-linked immunoabsorbent assay. Furthermore, proteins of the cells were collected for two-dimensional electrophoresis and the differential protein expression was identified by the matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry.
RESULT(S): Addition of soluble IL-1RII (2.0 microg/mL) significantly inhibited IL-1 beta-induced IL-6 and IL-8 secretion by endometrial cells in vitro. Infection of endometrial cells with rAd-RII significantly decreased IL-1 beta-induced IL-8 secretion, compared with the PBS and rAd-LacZ controls but had no significant effect on IL-6 secretion. Proteins of the infected cells were collected for two-dimensional electrophoresis, and intensities of 62 spots were significantly increased or decreased when compared with those in the PBS group. Thirty-four proteins were identified by MALDI-TOF mass spectrometry. The majority of the identified proteins are related to cellular metabolism and proliferation.
CONCLUSION(S): These results suggest that IL-1RII can neutralize IL-1 beta and counteract its effect on endometrial stromal cells, and may provide a new clinical strategy for the treatment of endometriosis.
确定Ⅱ型白细胞介素-1受体（IL-1RII）在子宫内膜异位症发病机制中的作用。
将子宫内膜细胞暴露于可溶性IL-1RII或IL-1RII重组腺病毒（rAd-RII）的培养实验。
妇科诊所及人类生殖研究实验室。
接受子宫切除术的子宫内膜异位症女性。
加入可溶性IL-1RII或感染rAd-RII 12小时后收集细胞培养基。
通过酶联免疫吸附测定法测量培养基中IL-6和IL-8的水平。此外，收集细胞蛋白进行二维电泳，并通过基质辅助激光解吸/电离飞行时间（MALDI-TOF）质谱法鉴定差异蛋白表达。
加入可溶性IL-1RII（2.0微克/毫升）显著抑制体外IL-1β诱导的子宫内膜细胞IL-6和IL-8分泌。与PBS和rAd-LacZ对照组相比，rAd-RII感染子宫内膜细胞显著降低IL-1β诱导的IL-8分泌，但对IL-6分泌无显著影响。收集感染细胞的蛋白进行二维电泳，与PBS组相比，62个斑点的强度显著增加或降低。通过MALDI-TOF质谱法鉴定出34种蛋白质。大多数鉴定出的蛋白质与细胞代谢和增殖有关。
这些结果表明，IL-1RII可以中和IL-1β并抵消其对子宫内膜基质细胞的作用，可能为子宫内膜异位症的治疗提供新的临床策略。
